Jeff Yass’s CG Oncology CGON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$18.2M Buy
256,192
+240,539
+1,537% +$17.7M ﹤0.01% 2567
2026
Q2
$1.11M Sell
15,653
-10,150
-39% -$663K ﹤0.01% 7927
2026
Q1
$1.75M Buy
+25,803
New +$1.46M ﹤0.01% 6488
2025
Q3
– Sell
-93,793
Closed -$2.73M – 12530
2025
Q2
$2.44M Buy
93,793
+11,808
+14% +$285K ﹤0.01% 5376
2025
Q1
$2.01M Buy
81,985
+44,316
+118% +$1.25M ﹤0.01% 5536
2024
Q4
$1.08M Buy
37,669
+24,676
+190% +$844K ﹤0.01% 6755
2024
Q3
$490K Buy
+12,993
New +$455K ﹤0.01% 8508
2024
Q2
– Sell
-11,149
Closed -$386K – 12125
2024
Q1
$489K Buy
+11,149
New +$455K ﹤0.01% 8569

Other funds holding CGON

Jeff Yass's CGON Position: Q3 2026 in Review

Jeff Yass increased its CG Oncology (CGON) stake by 1,537% in Q3 2026, buying an estimated $17.7M and bringing the position to 256,192 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Jeff Yass first reported a position in CGON in Q1 2024 and has held it in 8 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q3 2026.

  • Jeff Yass held 256,192 shares of CG Oncology worth $18.2M as of Q3 2026.
  • Jeff Yass bought 240,539 CG Oncology shares in Q3 2026, an estimated $17.7M.
  • CG Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #2567 holding.
  • Jeff Yass first reported a position in CG Oncology in Q1 2024 and has held it in 8 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.